The GIPET technology is an advanced-stage permeation enhancement oral drug-delivery platform based on enhancers that have
been studied in cells, tissues, rodents, dogs, and humans to demonstrate their ability to promote drug absorption, safety,
reversibility, and mechanism of action. The technology is suitable for a wide range of different molecule types as evidenced
by the preclinical and clinical studies showing enhanced intestinal absorption.
The authors thank David Brayden, professor at the University College Dublin in Ireland for critical reading of the manuscript.
The authors also want to acknowledge that the work of Edwin Walsh is funded by an Irish Research Council for Science, Engineering
and Technology (IRCSET)–Industry Partnership between the Irish Government and Merrion Pharmaceuticals.
Edwin G. Walsh, BSc, is a PhD student at the School of Veterinary Medicine and Conway Institute, University College Dublin, in Dublin, Ireland.
Alan P. Cullen, MSc, is preclinical development manager, John S. Fox, PhD, MBA, is chief development officer, and Thomas W. Leonard*, RPh, PhD, is vice-president and chief scientific officer, all at Merrion Pharmaceuticals, 219 Racine Drive, Suite D, Wilmington,
NC 28403, tel. 910.799.1847, fax 910.395,1843, email@example.com
1. E. Windsor and G.E. Cronheim, Nature
190 (4772), 263–264 (1961).
2. M. Hayashi, M. Tomita, and A. Awazu, Adv. Drug Deliv. Rev.
28 (2), 191–204 (1997).
3. T. Lindmark, T. Nikkila, and P. Artursson, J. Pharmacol. Exp. Ther.
275 (2), 958–964 (1995).
4. H. Huang and R.E. Verall, J. Solution Chem. 26 (2) 135–162 (1997).
5. Y. Lo and J. Huanh, Biochem. Pharmacol. 59 (6), 665–672 (2000).
6. JECFA, 29th Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series No. 733 (1986).
7. L. Blomquist, Gastroenterol. 32 (8), 805–812 (1997).
8. A.J. Ryan, R-T. Chang, and C.V. Gisolfi, Med. & Sci. in Sports & Exerc.
28 (6), 698–705 (1996).
9. T.T. Kararli, Biopharm. Drug Dispos.
16 (5), 351–380 (1995).